Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Share-based Compensation (2018 - 2025)

TransMedics has reported Share-based Compensation over the past 8 years, most recently at $9.4 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $9.4 million for Q4 2025, down 12.74% from a year ago — trailing twelve months through Dec 2025 was $36.9 million (up 10.95% YoY), and the annual figure for FY2025 was $36.9 million, up 10.95%.
  • Share-based Compensation for Q4 2025 was $9.4 million at TransMedics, up from $9.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for TMDX hit a ceiling of $10.8 million in Q4 2024 and a floor of $1.1 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $5.1 million (2023), compared with a mean of $5.4 million.
  • Biggest five-year swings in Share-based Compensation: surged 188.83% in 2021 and later dropped 12.74% in 2025.
  • TransMedics' Share-based Compensation stood at $2.0 million in 2021, then soared by 50.68% to $3.0 million in 2022, then soared by 91.37% to $5.7 million in 2023, then soared by 88.1% to $10.8 million in 2024, then dropped by 12.74% to $9.4 million in 2025.
  • The last three reported values for Share-based Compensation were $9.4 million (Q4 2025), $9.1 million (Q3 2025), and $9.4 million (Q2 2025) per Business Quant data.